2024年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20240689

中华皮肤科杂志 ›› 2025, e20240689.doi: 10.35541/cjd.20240689

• 综述 • 上一篇

2024年系统性红斑狼疮研究新进展

罗帅寒天¹ 龙海¹ 陆前进²

¹中南大学湘雅二医院皮肤性病科，长沙 410011；²中国医学科学院皮肤病医院中国医学科学院免疫性皮肤病基础与转化研究重点实验室，南京 210042

收稿日期:2024-12-16 修回日期:2025-01-14 发布日期:2025-05-12
通讯作者: 陆前进 E-mail:qianlu5860@pumcderm.cams.cn
基金资助:
国家自然科学基金（82273540）；国家级人才支持计划（Q2023230）；湖南省科技创新计划项目（2023RC1031）；中国医学科学院中央级公益性科研院所基本科研业务费专项资金（2021-RC320-001、2020-RC320-003）；中国医学科学院医学与健康科技创新工程项目（2021-I2M-1-059）

Research advances in systemic lupus erythematosus in 2024

Luo Shuaihantian¹, Long Hai¹, Lu Qianjin²

¹Department of Dermatology, the Second Xiangya Hospital of Central South University, Changsha 410011, China; ²Key Laboratory of Immunological Dermatology and Translational Research, Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2024-12-16 Revised:2025-01-14 Published:2025-05-12
Contact: Lu Qianjin E-mail:qianlu5860@pumcderm.cams.cn
Supported by:
National Natural Science Foundation of China （82273540）; National Talent Support Program （Q2023230）; Hunan Science and Technology Innovation Project （2023RC1031）; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences （2021-RC320-001, 2020-RC320-003）; CAMS Innovation Fund for Medical Sciences （2021-I2M-1-059）

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮是一种好发于年轻女性、累及多个器官系统的复杂自身免疫性疾病。本文综述2024年国内外研究者在系统性红斑狼疮发病机制和治疗管理等方面取得的一系列研究成果。

关键词: 红斑狼疮, 系统性, 治疗, 发病机制, 研究进展

Abstract: 【Abstract】 Systemic lupus erythematosus is a complex autoimmune disease predominantly affecting young women, and can involve multiple organs and systems. In 2024, significant advancements have been made in the research on systemic lupus erythematosus, particularly in the aspects of pathogenesis and treatment. This review summarizes the major progress achieved in these aspects.

Key words: Lupus erythematosus, systemic, Therapy, Pathogenesis, Research advance

罗帅寒天龙海陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025,e20240689. doi:10.35541/cjd.20240689

Luo Shuaihantian, Long Hai, Lu Qianjin. Research advances in systemic lupus erythematosus in 2024[J]. Chinese Journal of Dermatology,2025,e20240689. doi:10.35541/cjd.20240689

参考文献 22

［1］	Chi W, Kang N, Sheng L, et al. MCT1⁃governed pyruvate metabolism is essential for antibody class⁃switch recombination through H3K27 acetylation［J］. Nat Commun, 2024,15（1）:163. doi: 10.1038/s41467⁃023⁃44540⁃0.
［2］	Dou DR, Zhao Y, Belk JA, et al. Xist ribonucleoproteins promote female sex⁃biased autoimmunity［J］. Cell, 2024,187（3）:733⁃749.e16. doi: 10.1016/j.cell.2023.12.037.
［3］	Wu Z, Zheng Y, Sheng J, et al. CD3（+）CD4（-）CD8（-）（double⁃negative） T cells in inflammation, immune disorders and cancer［J］. Front Immunol, 2022,13:816005. doi: 10.3389/fimmu.2022. 816005.
［4］	Zhang Y, Du L, Wang C, et al. Neddylation is a novel therapeutic target for lupus by regulating double negative T cell homeostasis［J］. Signal Transduct Target Ther, 2024,9（1）:18. doi: 10.1038/s41392⁃023⁃01709⁃9.
［5］	Jiang H, Shen Z, Zhuang J, et al. Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy［J］. Front Immunol, 2023,14:1335936. doi: 10.3389/fimmu.2023.1335936.
［6］	Ye B, Chen B, Guo C, et al. C5a⁃C5aR1 axis controls mitochondrial fission to promote podocyte injury in lupus nephritis［J］. Mol Ther, 2024,32（5）:1540⁃1560. doi: 10.1016/j.ymthe.2024.03.003.
［7］	Chen W, Jin B, Cheng C, et al. Single⁃cell profiling reveals kidney CD163（+） dendritic cell participation in human lupus nephritis［J］. Ann Rheum Dis, 2024,83（5）:608⁃623. doi: 10. 1136/ard⁃2023⁃224788.
［8］	Biniaris⁃Georgallis SI, Aschman T, Stergioula K, et al. Amplification of autoimmune organ damage by NKp46⁃activated ILC1s［J］. Nature, 2024,634（8035）:952⁃960. doi: 10.1038/s41586⁃024⁃07907⁃x.
［9］	Ishina IA, Zakharova MY, Kurbatskaia IN, et al. MHC classⅡ presentation in autoimmunity［J］. Cells, 2023,12（2）:314. doi: 10.3390/cells12020314.
［10］	Mori S, Kohyama M, Yasumizu Y, et al. Neoself⁃antigens are the primary target for autoreactive T cells in human lupus［J］. Cell, 2024,187（21）:6071⁃6087.e20. doi: 10.1016/j.cell.2024.08.025.
［11］	Tian J, Shi L, Zhang D, et al. Dysregulation in keratinocytes drives systemic lupus erythematosus onset［J］. Cell Mol Immunol, 2025,22（1）:83⁃96. doi: 10.1038/s41423⁃024⁃01240⁃z.
［12］	Hiraoka D, Ishizaki J, Yamanouchi J, et al. Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus⁃formation analysis system （T⁃TAS）［J］. Lupus Sci Med, 2024,11（2）:e001223. doi: 10.1136/lupus⁃2024⁃001223.
［13］	Doglio M, Alexander T, Del Papa N, et al. New insights in systemic lupus erythematosus: from regulatory T cells to CAR⁃T⁃cell strategies［J］. J Allergy Clin Immunol, 2022,150（6）:1289⁃1301. doi: 10.1016/j.jaci.2022.08.003.
［14］	Doglio M, Ugolini A, Bercher⁃Brayer C, et al. Regulatory T cells expressing CD19⁃targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus［J］. Nat Commun, 2024,15（1）:2542. doi: 10.1038/s41467⁃024⁃46448⁃9.
［15］	Rovin BH, Furie RA, Ross Terres JA, et al. Kidney outcomes and preservation of kidney function with obinutuzumab in patients with lupus nephritis: a post hoc analysis of the NOBILITY trial［J］. Arthritis Rheumatol, 2024,76（2）:247⁃254. doi: 10.1002/art.42734.
［16］	Wang W, He S, Zhang W, et al. BCMA⁃CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open⁃label clinical trial［J］. Ann Rheum Dis, 2024,83（10）:1304⁃1314. doi: 10.1136/ard⁃2024⁃225785.
［17］	Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma［J］. N Engl J Med, 2022,387（6）:495⁃505. doi: 10.1056/NEJMoa2203478.
［18］	Alexander T, Krönke J, Cheng Q, et al. Teclistamab⁃induced remission in refractory systemic lupus erythematosus［J］. N Engl J Med, 2024,391（9）:864⁃866. doi: 10.1056/NEJMc2407150.
［19］	Strasser DS, Froidevaux S, Sippel V, et al. Preclinical to clinical translation of cenerimod, a novel S1P（1） receptor modulator, in systemic lupus erythematosus［J］. RMD Open, 2020,6（2）:e001261. doi: 10.1136/rmdopen⁃2020⁃001261.
［20］	Mueller MS, Juif PE, Charfi H, et al. Multiple⁃dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination［J］. J Clin Pharmacol, 2024,64（12）:1566⁃1575. doi: 10.1002/jcph.6106.
［21］	Cai T, Lenoir Capello R, Pi X, et al. Structural basis of γ chain family receptor sharing at the membrane level［J］. Science, 2023,381（6657）:569⁃576. doi: 10.1126/science.add1219.
［22］	Yin H, Li L, Feng X, et al. 2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus［J］. Signal Transduct Target Ther, 2024,9（1）:323. doi: 10.1038/s41392⁃024⁃02017⁃6.

[1]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 中国难治性慢性自发性荨麻疹诊治指南（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 485-496.
[2]	黄雪薇陈奇权杨显杰陈安祺王欢邓思思翟志芳王娟宋志强. 荨麻疹性血管炎与伴色素沉着慢性自发性荨麻疹的临床与病理特征对比分析[J]. 中华皮肤科杂志, 2025, 58(6): 508-514.
[3]	邱里肖汀. 布鲁顿酪氨酸激酶抑制剂在慢性自发性荨麻疹治疗中的进展[J]. 中华皮肤科杂志, 2025, 58(6): 563-567.
[4]	于金蕾吴桥芳孙悦鑫包军周映. 佩索利单抗治疗6例泛发性脓疱型银屑病临床观察[J]. 中华皮肤科杂志, 2025, 0(5): 20240440-e20240440.
[5]	白璐楚妍刘园园朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2025, 58(5): 477-480.
[6]	黄和金李馨雅席文文肖霞蒋斌杨锋. 微创旋切术治疗腋臭患者3 000例术后并发症回顾分析[J]. 中华皮肤科杂志, 2025, 0(5): 20230291-e0230291.
[7]	中国儿童鲜红斑痣诊断和治疗专家共识制订专家组中国医师协会皮肤科医师分会儿童学组. [开放获取] 儿童鲜红斑痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 396-404.
[8]	中国医师协会皮肤科医师分会中华医学会皮肤病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. 大疱性类天疱疮诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 405-415.
[9]	中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组中国抗癌协会黑色素瘤专业委员会中国抗癌协会皮肤肿瘤整合康复专业委员会. [开放获取] 色素痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 387-395.
[10]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 特应性皮炎达标门诊建设标准专家共识（2025基层版）[J]. 中华皮肤科杂志, 2025, 0(4): 20240296-e20240296.
[11]	李紫钰鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383.
[12]	许秋云纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 中华皮肤科杂志, 2025, 58(4): 369-373.
[13]	吕铭悦满孝勇. 细胞治疗在系统性红斑狼疮中的应用[J]. 中华皮肤科杂志, 2025, 58(4): 374-377.
[14]	包诗杰韩梅周小勇. 基于文献回顾的依那西普治疗中毒性表皮坏死松解症疗效影响因素分析[J]. 中华皮肤科杂志, 2025, 58(4): 352-355.
[15]	万勇军杨海晶严翘陈梅王逢源粟倩雅董正邦王飞. 免疫检查点抑制剂相关Stevens-Johnson综合征/中毒性表皮坏死松解症9例临床及预后分析[J]. 中华皮肤科杂志, 2025, 58(4): 347-351.

2024年系统性红斑狼疮研究新进展

Research advances in systemic lupus erythematosus in 2024

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

Metrics

本文评价

推荐阅读 10